The role of psychostimulants in fatal stroke among young people
The study will examine all cases of fatal stroke in Australia amongst young people (<45 years) over the period 2009-2016 to determine the role of psychostimulants in these events.
The study will examine all cases of fatal stroke in Australia amongst young people (<45 years) over the period 2009-2016 to determine the role of psychostimulants in these events.
NDARC has been invited to undertake research in partnership with NSW Aboriginal drug and alcohol Residential Rehabilitation Services. This research is unique in being embedded into the routine delivery of their services.
Alcohol and other drug (AOD) treatment is key for improving health and reducing the social impact of AOD use. However, the treatment itself is not the only variable that impacts on whether health outcomes are improved.
This project is an international collaboration to assess the nature and extent of health outcomes from drug cryptomarkets, globally and specifically for Australians.
This project seeks to develop knowledge about effective models of partnership between rural Aboriginal communities and researchers across a range of community-led programs delivered from 2012-2016, which aimed to reduce drug and alcohol-related harm.
Substance use among pregnant women is a significant public health issue. A range of adverse effects have been noted including increased risk of miscarriage and still birth, reduction in fetal growth, birth defects, developmental delay, growth retardation and neurological abnormalities.
Substance use amongst adolescents (those in the age group of 10-19) is an important public health issue in many countries of the region.
It has been argued that the increased influence of conservative advocacy groups and the impact of the political social conservatism of ‘The Howard Years’ has led to a conservative shift in Australian drug policy, away from harm minimisation and towards a zero tolerance model (Mendes, 2001,
The IDAT Program, established under the Drug and Alcohol Treatment Act 2007 of New South Wales, aims to “provide short-term care, with an involuntary supervised withdrawal component, to protect the health and safety of people with severe substance dependence who have experienced, or are at risk o